Literature DB >> 15636435

Elevated bone resorption markers in a patient with hypercalcemia associated with post-partum thyrotoxicosis and hypoadrenocorticism due to pituitary failure.

M Fujikawa1, K Kamihira, K Sato, K Okamura, S Kidota, M Lida.   

Abstract

A 36-yr-old woman began to suffer from headache, anorexia and general fatigue at 35 weeks' gestation. About 2 or 3 months after the delivery, fever, tachycardia and generalized musculoskeletal disorder appeared. Thereafter, they worsened rapidly, accompanied by a disturbance of consciousness and hypercalcemia. Thyrotoxicosis, due to a post-partum thyroiditis, and glucocorticoid deficiency, due to a pituitary failure, probably associated with lymphocytic hypophysitis, were also observed. All the symptoms and hypercalcemia disappeared after the glucocorticoid replacement therapy and the normalization of thyroid hormone levels. Serum and urinary bone resorption markers, such as urine pyridinoline (U-Pyr), urine deoxypyridinoline (U-DPD), urine amino-terminal telopeptide of type I collagen (U-NTx) and serum carboxy-terminal telopeptide of type I collagen (ICTP), were extremely high at the hypercalcemic state. In this case, they were 10 to 20 times higher than the normal upper limits, and then markedly decreased in a normocalcemic state, thereby showing an extreme acceleration of bone resorption in a state of both thyrotoxicosis and glucocorticoid deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15636435     DOI: 10.1007/BF03347524

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

Review 2.  Thyroid hormones and bone.

Authors:  T J Allain; A M McGregor
Journal:  J Endocrinol       Date:  1993-10       Impact factor: 4.286

Review 3.  Regulation of bone formation.

Authors:  L G Raisz; B E Kream
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

4.  Etiology of hypercalcemia in a patient with Addison's disease.

Authors:  E Muls; R Bouillon; J Boelaert; G Lamberigts; S Van Imschoot; R Daneels; P De Moor
Journal:  Calcif Tissue Int       Date:  1982       Impact factor: 4.333

5.  Bone-resorbing activity of thyroid hormones is related to prostaglandin production in cultured neonatal mouse calvaria.

Authors:  K Klaushofer; O Hoffmann; H Gleispach; H J Leis; E Czerwenka; K Koller; M Peterlik
Journal:  J Bone Miner Res       Date:  1989-06       Impact factor: 6.741

6.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.

Authors:  P D Delmas; A Schlemmer; E Gineyts; B Riis; C Christiansen
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

7.  Triiodothyronine potentiates the stimulatory effects of interleukin-1 beta on bone resorption and medium interleukin-6 content in fetal rat limb bone cultures.

Authors:  G Tarjan; P H Stern
Journal:  J Bone Miner Res       Date:  1995-09       Impact factor: 6.741

8.  Life-threatening hypercalcaemia in association with Addisonian crisis.

Authors:  J Miell; W Wassif; A McGregor; J Butler; R Ross
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

9.  Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.

Authors:  S P Robins; H Woitge; R Hesley; J Ju; S Seyedin; M J Seibel
Journal:  J Bone Miner Res       Date:  1994-10       Impact factor: 6.741

10.  Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.

Authors:  A M Parfitt; L S Simon; A R Villanueva; S M Krane
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

View more
  4 in total

1.  Adrenal crisis presented as acute onset of hypercalcemia and hyponatremia triggered by acute pyelonephritis in a patient with partial hypopituitarism and pre-dialysis chronic kidney disease.

Authors:  Shunsuke Yamada; Hokuto Arase; Toshifumi Morishita; Akihiro Tsuchimoto; Kumiko Torisu; Takehiro Torisu; Kazuhiko Tsuruya; Toshiaki Nakano; Takanari Kitazono
Journal:  CEN Case Rep       Date:  2018-11-19

2.  Life-Threatening Hypercalcemia due to Graves' Disease and Concomitant Adrenal Failure: A Case Report and Review of the Literature.

Authors:  Hande Mefkure Ozkaya; Fatma Ela Keskin; Ozlem Asmaz Haliloglu; Tugba Elif Senel; Pinar Kadioglu
Journal:  Case Rep Endocrinol       Date:  2015-03-24

3.  Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate.

Authors:  Erina Yuasa-Shibasaki; Sumiyasu Ishii; Shunichi Matsumoto; Takuya Tomaru; Kazuhiko Horiguchi; Aya Osaki; Atsushi Ozawa; Nobuyuki Shibusawa; Tetsurou Satoh; Masanobu Yamada
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

4.  Infants With Congenital Adrenal Hyperplasia Are at Risk for Hypercalcemia, Hypercalciuria, and Nephrocalcinosis.

Authors:  Melissa J Schoelwer; Vidhya Viswanathan; Amy Wilson; Corina Nailescu; Erik A Imel
Journal:  J Endocr Soc       Date:  2017-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.